Utility of the ACE Inhibitor Captopril in Mitigating Radiation-Associated Pulmonary Toxicity in Lung Cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 41, Issue 4, 2018, Pages 396-401

  Small, William ^a   James, Jennifer L ^b   Moore, Timothy D ^c   Fintel, Dan J ^d   Lutz, Stephen T ^e   Movsas, Benjamin ^f   Suntharalingam, Mohan ^g   Garces, Yolanda I ^h   Ivker, Robert ⁱ   Moulder, John ^j   Pugh, Stephanie ^b   Berk, Lawrence B ^k  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b NRG ONCOLOGY STATISTICS AND DATA MANAGEMENT CENTER   (United States)

^c Department of Hematology Oncology   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e Blanchard Valley Health Association   (United States)

^f HENRY FORD HEALTH SYSTEM   (United States)

^g UNIVERSITY OF MARYLAND   (United States)

^h MAYO CLINIC   (United States)

ⁱ NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^j MEDICAL COLLEGE OF WISCONSIN   (United States)

^k H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

more..

Author keywords

captopril; lung cancer; pneumonitis; radiotherapy

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; DRUG DOSE ESCALATION; FEMALE; HUMAN; MALE; MULTICENTER STUDY (TOPIC); NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); RADIATION PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMALL CELL LUNG CANCER; VERY ELDERLY; CLINICAL TRIAL; CONFORMAL RADIOTHERAPY; CONTROLLED STUDY; FOLLOW UP; LUNG TUMOR; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; QUALITY OF LIFE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; QUALITY OF LIFE; RADIATION INJURIES; RADIATION PNEUMONITIS; RADIOTHERAPY, CONFORMAL;

EID: 84964334204     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000289     Document Type: Article

References (20)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Marks LB, Bentzen SM, Deasy JO, et al. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys. 2010;76(suppl 1): S70-S76.
3. Ward WF, Kim YT, Molteni A, et al. Radiation-induced pulmonary endothelial dysfunction in rats: modification by an inhibitor of angiotensin converting enzyme. Int J Radiat Oncol Biol Phys. 1988;15:135-140.
4. Ward WF, Lin PJ, Wong PS, et al. Radiation pneumonitis in rats and its modification by the angiotensin-converting enzyme inhibitor captopril evaluated by high-resolution computed tomography. Radiat Res. 1993;135:81-87.
5. Molteni A, Moulder JE, Cohen EP, et al. Control of radiationinduced pneumopathy and lung fibrosis by angiotensin converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Radiat Biol. 2000;76:523-532.
6. Cohen EP, Molteni A, Hill P, et al. Captopril preserves function and ultrastructure in experimental radiation nephropathy. Lab Invest. 1996;75:349-360.
7. Stone HB, Moulder JE, Coleman CN, et al. Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI workshop, December 3-4, 2003. Radiat Res. 2004;162:711-728.
8. Moulder JE, Cohen EP, Fish BL. Captopril and losartan for mitigation of renal injury caused by single-dose total body irradiation. Radiat Res. 2011;175:29-36.
9. Cohen EP, Bedi M, Irving AA, et al. Mitigation of late renal and pulmonary injury after hematopoietic stem cell transplantation. Int J Radiat Oncol Biol Phys. 2012;83:292-296.
10. Kharofa J, Cohen EP, Tomic R, et al. Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensinconverting enzyme inhibitors and thoracic radiation therapy. Int J Radiat Oncol Biol Phys. 2012;84:238-243.
11. Bezjak A, Soyfer V, Yi Q, et al. Radiation pneumonitis in lung cancer patients-The neglected patient-related variables. Int J Radiat Oncol Biol Phys. 2005;63(suppl 1):S229.
12. Jenkins P, Watts J. An improved model for predicting radiation pneumonitis incorporating clinical and dosimetric variables. Int J Radiat Oncol Biol Phys. 2011;80:1023-1029.
13. Hartsell WF, Scott CB, Dundas GS, et al. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03. Am J Clin Oncol. 2007;30: 368-376.
14. Zelen M. The randomization and stratification of patients to clinical trials. J Chronic Dis. 1974;27:365-375.
15. Rubin P, Casarett GW, eds. Respiratory system. Clinical Radiation Pathology. Philadelphia: W. B. Saunders Co.; 1968:423-470.
16. Evans RF, Sagerman RH, Ringrose TL, et al. Pulmonary function following mantle-field irradiation for Hodgkins disease. Radiology. 1974;111:729-731.
17. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for nonsmall cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999;45:323-329.
18. Perez CA, Bauer M, Edelstein S, et al. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys. 1986;12:539-547.
19. Movsas B, Vikram B, Hauer-Jensen M, et al. Decreasing the adverse effects of cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators. Clin Cancer Res. 2010;17:222-228.
20. Kohl RR, Kolozsvary A, Brown SL, et al. Differential radiation effect in tumor and normal tissue after treatment with ramipril, an angiotensin-converting enzyme inhibitor. Radiat Res. 2007;168: 440-445.